Navigation Links
Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
Date:3/30/2009

CRANBURY, N.J., March 30 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company's Chief Operating Officer, Matthew R. Patterson, will be presenting at the upcoming 16th Annual Future Leaders in the Biotech Industry conference at New York City's Millennium Broadway Hotel and Conference Center. Mr. Patterson's presentation is scheduled to begin on Thursday, April 2, 2009 at 9:30 a.m. EDT.

Individuals can listen to a live webcast of the presentation by logging on to the Investors section of the Amicus Therapeutics' Web site, www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 90 days.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
2. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
3. Amicus Therapeutics Announces Change to Board of Directors
4. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
5. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
6. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
7. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
8. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
10. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
11. Amicus Therapeutics Opens Research Facility in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... DuPont Pioneer ... exclusive rights to the ERS patent portfolio covering CRISPR-Cas genome editing technology for ... foundational intellectual property (IP) of the CRISPR-Cas technology from co-inventor and co-owner Emmanuelle ...
(Date:6/23/2017)... ... 2017 , ... Biova, LLC., the leader in water soluble egg membrane ingredients, ... Henig will bring a wealth of scientific experience in the food, beverage, nutrition and ... Scientific Officer of four major global companies in the last 4 decades. He ...
(Date:6/22/2017)... ... 21, 2017 , ... Beaker, the industry’s pioneer in developing ... sciences industry, today announces a strategic partnership with Alcami Corporation, a leading global ... Beaker’s expertise in executive recruitment solutions, providing Alcami with access to the best ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... RegMedNet has produced a Spotlight series on “Cell Therapy ... and perspectives by leading experts on the unique regulatory challenges of stem cell ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):